MBX vs CELC
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
MBX · MBX Biosciences$49.55 ▼ 7.23%
CELC · Celcuity$53.35 ▼ 5.26%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- MBX +58.6%
- CELC -47.3%
Head to head
| Metric | MBX | CELC |
|---|---|---|
| Price | $49.55 | $53.35 |
| Change today | ▼ 7.23% | ▼ 5.26% |
| Market cap | $2.46B | $2.62B |
| Return, 3 months | -25.4% | -41.2% |
| Return, year to date | +57.1% | -46.5% |
| Return, 1 year | +83.0% | -45.3% |
| P/E (TTM) | – | – |
| P/B | 5.2 | -35.4 |
| P/E percentile vs own 5y | 26th | 25th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | – | – |
| Net profit growth (YoY) | -188.7% | -67.4% |
| Gross margin | – | – |
| Operating margin | – | – |
| Net margin | – | – |
| Return on equity | -33.7% | -1,192.9% |
| Analyst target vs. price | +98.4% | +176.7% |
| Analyst buy share | 100% | 100% |
| RSI (14) | 41 | 30 |
| 30-day volatility | 66.3% | 61.9% |
| Max drawdown, 1 year | -37.6% | -63.2% |
| Trend read | Leaning bearish | Strong downtrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- CELC is the largest of the group by market value.
- MBX has returned the most over the past year.
- CELC has been the calmest stock over the last 30 days.